3006 The effects of spirulina (Arthrospira platensis) dietary supplement as an adjunct therapy for children aged 7 to 14 years old with asthma: A randomized - double blind placebo controlled clinical trial

Friday, 16 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)

Lou Ver Leigh Arciaga Manzon, MD, DPPS , Pediatric Allergology and Clinical Immunology, University of Santo Tomas Hospital, Manila, Philippines

Pilar Agnes Gonzalez Andaya, MD , Pediatrics, Section of Allergy & Immunology, University of Santo Tomas Faculty of Medicine, Manila, Philippines

A) Background: The anti-inflammatory effect of Spirulina has been demonstrated to inhibit histamine release from mast cell-mediated allergic reactions. Studies have documented the anti-inflammatory and immunomodulatory properties of supplementation as an adjunct therapy for asthma.

B) Methods: This is a randomized, double-blind, placebo-controlled study wherein children 7 to 14 years old diagnosed with mild to moderate persistent asthma were randomly assigned to receive either Spirulina (1,000 mg to 2,000 mg daily) or placebo for three months. Asthma Control Test (ACT) and Composite Asthma Severity Index (CASI) were used for patient report-based measures. Forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC and peak expiratory flow rate (PEFR) were determined through spirometry. Post-supplementation assessment for three months was done. 

C) Results: A total of 39 patients (Spirulina = 20, placebo = 19) were enrolled in this trial. During the supplementation phase, both the Spirulina and placebo groups showed significant improvement in ACT scores (Spirulina, P < 0.0001; placebo, P = 0.19) compared to baseline. There was no significant change in CASI scores in both groups. However, during post-supplementation phase, the Spirulina group showed significantly sustained improvement on both the ACT (P < 0.0001) and CASI scores (P < 0.0001) compared to placebo. The FEV1 (P = 0.014), FVC (P = 0.008), and PEFR (P = 0.0001) of the Spirulina group significantly improved by the end of supplementation. Overall, significant intergroup differences  revealed  only  in  FEV1(P = 0.0002) and PEFR (P< 0.0001).

D) Conclusion: Daily supplementation with Spirulina significantly improved asthma control, FEV1 and PEFR compared to placebo.